Clinical Trial Update: Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma [Phase 2]

View source ↗

Summary

This entry describes a Phase 2 clinical trial of low-dose mosunetuzumab for indolent B-cell lymphomas, currently recruiting at the University of Washington and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Marginal Zone Lymphoma

Drugs mentioned

• Mosunetuzumab (mosunetuzumab)

Snippet

Sponsor: University of Washington | Conditions: Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma | Phase 2 | Status: RECRUITING